TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07915219: An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

Sponsor: Boehringer Ingelheim · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,414,320

Rescue Site Savings

+$942,880

Unlock Full NCT07915219 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07915219 Rescue Dossier →